局部晚期乳腺癌新辅助化疗十年疗效评价与影响因素分析

 目的 探讨乳腺癌新辅助化疗十年疗效及影响患者预后的因素。方法 回顾性收集190例接受新辅助化疗的局部晚期乳腺癌患者的临床病理资料,检测新辅助化疗后病理完全缓解率(pCR),完成十年随访,分析影响患者长期预后的因素。结果 190例中,新辅助化疗后达病理完全缓解者共22例(11.58%)。单因素分析显示Ki-67表达水平、化疗方案和Luminal分型与pCR相关(P均<0.05),多因素分析显示Ki-67的表达水平是影响新辅助化疗后病理完全缓解的独立因素(P＜0.05)。该组患者10年总生存率为56.3%,pCR是新辅助化疗乳腺癌患者预后的独立影响因素(P＜0.05)。结论 Ki-67是影响乳腺癌新辅助化疗后病理完全缓解的独立因素;pCR是新辅助化疗乳腺癌患者预后的独立影响因素。

Long-term evaluation of neoadjuvant chemotherapy for breast cancer and influencing factors

Objective To explore the influencing factors of the curative effect and prognosis of patients with breast cancer who have undergone neoadjuvant chemotherapy.Methods The clinicopathologic data on 190 locally advanced breast cancer patients receiving neoadjuvant chemotherapy was retrospectively collected and the factors that influenced pathologic complete response and prognosis of patients after neoadjuvant chemotherapy were analyzed.Results Among the 190 patients, 22 cases (11.58%) had pathological complete response after neoadjuvant chemotherapy. Univariate analysis showed that the expression level of ki-67, chemotherapy regimen and Luminal typing were correlated with PCR (P<0.05). Multivariate analysis showed that the expression level of ki-67 was an independent factor influencing the pathological complete response after neoadjuvant chemotherapy (P<0.05). The overall 10-year survival rate was 56.3%. Multivariate analysis showed that PCR was an independent factor affecting the survival rate of breast cancer patients after neoadjuvant chemotherapy (P<0.05).Conclusions Ki-67 is an independent factor that affects pathological complete response after neoadjuvant chemotherapy for breast cancer while PCR is an independent factor influencing the prognosis of breast cancer patients after neoadjuvant chemotherapy.